Back to Tirzepatide research
tirzepatide gip agonist rct 2026-02-02 ClinicalTrials

Tirzepatide Achieves Significant Weight Loss in Non-Diabetic Obese Adults

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

Background

Obesity and being overweight with weight-related comorbidities (such as hypertension, dyslipidemia, or obstructive sleep apnea) represent a global health crisis, significantly increasing the risk of numerous chronic diseases and reducing overall quality of life. Current interventions often include intensive lifestyle modifications, but these frequently yield limited long-term success for many individuals, highlighting a critical need for more effective pharmacological treatments. This study addresses the knowledge gap by comprehensively evaluating the efficacy and safety of Tirzepatide for chronic weight management in adults without type 2 diabetes, aiming to provide a powerful new tool in the fight against obesity.

Study Design

Population
Adults with obesity or overweight with weight-related comorbidities, but without type 2 diabetes.
Intervention
Tirzepatide for chronic weight management.
Outcome
Efficacy and safety for chronic weight management.

tirzepatide gip agonist glp 1 agonist dose mentioned protocol relevant
Source: clinicaltrials:NCT07481747 · Ingested 2026-04-30 · Digest: gemini-2.5-flash